Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Current Deferred Revenue (2017 - 2022)

Historic Current Deferred Revenue for Summit Therapeutics (SMMT) over the last 6 years, with Q2 2022 value amounting to $3.2 million.

  • Summit Therapeutics' Current Deferred Revenue fell 5474.79% to $3.2 million in Q2 2022 from the same period last year, while for Jun 2022 it was $3.2 million, marking a year-over-year decrease of 5474.79%. This contributed to the annual value of $7.9 million for FY2021, which is 1118.69% down from last year.
  • Summit Therapeutics' Current Deferred Revenue amounted to $3.2 million in Q2 2022, which was down 5474.79% from $5.1 million recorded in Q1 2022.
  • Summit Therapeutics' Current Deferred Revenue's 5-year high stood at $8.9 million during Q4 2020, with a 5-year trough of -$35.9 million in Q2 2018.
  • Its 5-year average for Current Deferred Revenue is -$1.9 million, with a median of -$962358.6 in 2019.
  • In the last 5 years, Summit Therapeutics' Current Deferred Revenue crashed by 39827.07% in 2018 and then soared by 71201.57% in 2020.
  • Summit Therapeutics' Current Deferred Revenue (Quarter) stood at -$8.0 million in 2018, then surged by 81.79% to -$1.5 million in 2019, then surged by 712.02% to $8.9 million in 2020, then dropped by 11.19% to $7.9 million in 2021, then tumbled by 59.3% to $3.2 million in 2022.
  • Its Current Deferred Revenue stands at $3.2 million for Q2 2022, versus $5.1 million for Q1 2022 and $7.9 million for Q4 2021.